I am a medical oncologist dedicated to treating and studying diseases that affect the genitourinary system. My particular focus is on renal cell carcinoma (RCC), the most common form of kidney cancer in adults.
My scientific work involves ongoing clinical trial investigations of new interventions, novel targeted agents, and drug combination programs in kidney cancer treatment. Currently I lead a number of clinical trials that focus on treatment for rarer kidney cancers, such as non-clear cell kidney cancer. In collaboration with physician-scientist James Hsieh and geneticist Raju Chaganti, I do a lot of translational research on the progression of RCC, its resistance to therapies, biomarkers (early markers) for the illness, and outcomes.
At Memorial Sloan-Kettering I appreciate the ability to combine both clinical and science practice to provide the best possible care—and it works for our patients. I am grateful for the opportunities here to put my training and research straight to work each day toward improving medical care and interventions, and enhancing quality of life for patients and their families coping with cancer.